Second-line treatment for advanced non-small cell lung cancer: A systematic review
Authors:
- Fabrice BarlésiFBFabrice Barlési
- William JacotWJWilliam Jacot
- Philippe AstoulPAPhilippe Astoul
- Jean-Louis PujolJPJean-Louis Pujol
- 1 February 2006
- journal article
- review article
- Published by Elsevier in Lung Cancer
- Vol. 51 (2) , 159-172
Abstract
No abstract availableKeywords
This publication has 81 references indexed in Scilit:
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- Is the second line data on the use of docetaxel in non-small cell lung cancer reproducible?Lung Cancer, 2004
- Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancerEuropean Journal of Cancer, 2004
- A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal CancerJournal of Clinical Oncology, 2004
- Economic Analysis of the TAX 317 Trial: Docetaxel Versus Best Supportive Care as Second-Line Therapy of Advanced Non-Small-Cell Lung CancerJournal of Clinical Oncology, 2002
- Phase I/II trial of docetaxel and vinorelbine in patients with non-small cell lung cancer previously treated with platinum-based chemotherapyLung Cancer, 2001
- Gemcitabine and vinorelbine as second-line therapy in non-small-cell lung cancer after prior treatment with taxane+platinum-based regimensEuropean Journal of Cancer, 2001
- Regional plus systemic chemotherapy: an effective treatment in recurrent non-small cell lung cancerEuropean Journal of Surgical Oncology, 2001
- Second-line treatment with gemcitabine and vinorelbine in non-small-cell lung cancer (NSCLC) cisplatin failures: a pilot studyLung Cancer, 2000
- Polychemotherapy in advanced non small cell lung cancer: a meta-analysisThe Lancet, 1993